Privacy preference

MEDtalks would like to keep you informed about the content that is most relevant to you. Click here for more information.

Quarterly Focus on GU | Bladder Cancer

Publications in peer-reviewed journals are a major source for keeping up with the latest developments in your field. However, you may not always have sufficient time to study (difficult) publications thoroughly and to determine the impact on your clinical practice. To support you, MEDtalks Oncology has developed a new program format: the Quarterly Focus. This innovative program brings an expert panel and authors of relevant, selected publications together to explain and discuss the new data.

In this third episode of the Quarterly Focus on Genitourinary Cancer, two pivotal, international publications on Bladder Cancer from the past few months will be clarified by one of the authors and will be thoroughly discussed by an expert panel including the author. The program will give you the possibility to gain more insight into the selected publications.

The expert panel consist of:
Michiel van der Heijden, MD, PhD - medical oncologist, Netherlands Cancer Institute, Amsterdam
Prof. Fred Witjes, MD -  urologist, Radboudumc, Nijmegen
Sjoukje Oosting, MD, PhD - medical oncologist, UMCG, Groningen


Speaker: Prof. Dipen Parekh, MD – urologist at University of Miami Health System in Miami, USA
Robot-assisted radical cystectomy versus open radical cystectomy in patients with bladder cancer (RAZOR): an open-label, randomised, phase 3, non-inferiority trial
Lancet 391, 2018

Speaker: Michiel van der Heijden, MD, PhD, medical oncologist, Netherlands Cancer Institute, Amsterdam, The Netherlands
Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial
Lancet 391, 2017

  • Invited speakers

  • Michiel van der Heijden, MD

    medical oncologist

    NKI-AvL, Amsterdam

  • Sjoukje Oosting, MD

    medical oncologist

    UMCG, Groningen

  • Prof. Fred Witjes, MD


    Radboudumc, Nijmegen

  • Prof. Dipen Parekh, MD

    medical oncologist

    University of Miami Health System, Miami

  • Sponsors

    This program is editorially independent and is financially made possible by

Related items

Congresnieuws 13/12/2018

EMUC 2018: POUT trial

Dr. Alison Birtle (UK) is thrilled about the results of the POUT trial. This trial examined the benefit of adjuvant chemotherapy after nephroureterectomy in patients with upper tract urothelial carcinoma.

Congresnieuws 13/12/2018

EMUC 2018: POTOMAC & ALBAN trials

Dr. Evanguelos Xylinas, urologist at Cochin Hospital, Paris Descartes University (France), is chief editor of the bladder cancer section of the UROONCO educational platform and talks about the POTOMAC trial (durvalumab plus BCG vs. BCG) and the ALBAN trial (atezolizumab plus BCG vs. BCG).

Congresnieuws 12/09/2017

ESMO 2017 in-depth: RANGE trial

This year the ESMO congress took place in Madrid from 8 - 12 September. Daniel Petrylak, Professor of Medicine and Urology at Yale School of Medicine, explains the design and results of the RANGE trial. This phase III randomised trial evaluated the efficacy of ramucirumab in combination with docetaxel in patients with advanced urothelial cancer who failed prior platinum-based therapy.

Congresnieuws 18/02/2017

ASCO GU 2017: Discussion program on prostate and bladder cancer

On February 16-18, the 2017 Genitourinary Cancers Symposium took place in Orlando, Florida. An international multidisciplinary panel discussed a selection of topics and new data on prostate and bladder cancer. During a live connection, questions were submitted by participants of the ASCO Direct GU Virtual meetings in 7 different countries (Austria, Belgium, Brazil, Germany, Netherlands, United Arabic Emirates and Switzerland) Topics: Active surveillance in localized prostate cancer Impact of ProtecT trial results Value of imaging, genomics, and genetics for active surveillance High-risk prostate cancer, definition and therapeutic controversies Value of chemoradiation for bladder cancer Molecular predictors and response to neoadjuvant chemotherapy in bladder cancer Speakers: Prof. Bertrand Tombal MD PhD, urologist, Université catholique de Louvain, Cliniques universitaires Saint-Luc, Brussels, Belgium Prof. Robert Bristow MD PhD, radiation oncologist, Princess Margaret Hospital, Toronto, Canada Prof. Thomas Bauernhofer MD, medical oncologist, University Clinic for Internal Medicine Karl-Franzens University, Graz, Austria Neil Shore MD, urologist, Atlantic Urology Clinic, Myrtle Beach, USA Moderator: Catherine Hood PhD  

Congresnieuws 18/02/2017

ASCO-GU 2017: TEE during neoadjuvant chemotherapy for UCC

A selection of posters from the 2017 Genitourinary Cancers Symposium is highlighted in a series of interviews. Speaker: Syed Hussain Poster: B339 - Thrombo-embolic events (TEE) during neoadjuvant chemotherapy for muscle invasive bladder cance

Congresnieuws 18/02/2017

​ASCO GU 2017: Atezolizumab in mUCC

A selection of posters from the 2017 Genitourinary Cancers Symposium is highlighted in a series of interviews. Speaker: Daniel Petrylak Poster: B290 - Atezolizumab (atezo) in patients with metastatic urothelial carcinoma (mUC): A 2-year clinical update from a phase Ia study

Congresnieuws 18/02/2017

​ASCO GU 2017: Durvalumab in advanced UCC

A selection of posters from the 2017 Genitourinary Cancers Symposium is highlighted in a series of interviews. Speaker: Thomas Powles Poster: B286 - Updated efficacy and tolerability of durvalumab in locally advanced or metastatic urothelial carcinoma.

Congresnieuws 18/02/2017


A selection of posters from the 2017 Genitourinary Cancers Symposium is highlighted in a series of interviews. Speaker: Arjun Balar Poster: B284 - Pembrolizumab as first-line therapy in cisplatin-ineligible advanced urothelial cancer: Results from the total KEYNOTE-052 study population.